Circulating asymmetric dimethylarginine and lipid profile in pre-pubertal children with growth hormone deficiency: Effect of 12-month growth hormone replacement therapy

Growth Hormone and IGF Research

Volumn 24, Issue 5, 2014, Pages 216-220

  De Marco, S ^a   Marcovecchio, M L ^a   Caniglia, D ^a   De Leonibus, C ^a   Chiarelli, F ^a   Mohn, A ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

ADMA; Cardiovascular risk; Children; Growth hormone deficiency; Lipids

Indexed keywords

GROWTH HORMONE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; SOMATOMEDIN C; ARGININE; GLUCOSE BLOOD LEVEL; HUMAN GROWTH HORMONE; N,N-DIMETHYLARGININE;

AMINO ACID BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CAUCASIAN; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOCRINE SYSTEM EXAMINATION; FEMALE; GLUCOSE METABOLISM; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; PREPUBERTY; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; DEFICIENCY; DRUG EFFECTS; FOLLOW UP; GLUCOSE BLOOD LEVEL; GROWTH DISORDERS; INSULIN RESISTANCE; METABOLISM; PUBERTY; TIME;

ARGININE; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHILD; FEMALE; FOLLOW-UP STUDIES; GROWTH DISORDERS; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; MALE; PUBERTY; TIME FACTORS;

EID: 84907978299     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2014.08.001     Document Type: Article

References (40)

1. Colao A., Di Somma C., Savanelli M.C., De Leo M., Lombardi G. Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. Growth Hormon. IGF Res. 2006, 16(Suppl. A):S41-S48.
2. Capalbo D., Esposito A., Di Mase R., Barbieri F., Parenti G., Vajro P., Pignata C., Salerno M. Update on early cardiovascular and metabolic risk factors in children and adolescents affected with growth hormone deficiency. Minerva Endocrinol. 2012, 37:379-389.
3. Groban L., Lin M., Kassik K.A., Ingram R.L., Sonntag W.E. Early-onset growth hormone deficiency results in diastolic dysfunction in adult-life and is prevented by growth hormone supplementation. Growth Hormon. IGF Res. 2011, 21:81-88.
4. Gazzaruso C., Gola M., Karamouzis I., Giubbini R., Giustina A. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH-an update. J. Clin. Endocrinol. Metab. 2014, 99:18-29.
5. Capalbo D., Lo Vecchio A., Farina V., Spinelli L., Palladino A., Tiano C., Lettiero T., Lombardi G., Colao A., Salerno M. Subtle alterations of cardiac performance in children with growth hormone deficiency: results of a two-year prospective, case-control study. J. Clin. Endocrinol. Metab. 2009, 94:3347-3455.
6. Bailey-Downs L.C., Sosnowska D., Toth P., Mitschelen M., Gautam T., Hentorn J.C., Ballabh P., Koller A., Farley J.A., Sonntag W.E., Csiszar A., Ungvari Z. Growth hormone and IGF-1 deficiency exacerbate high-fat diet-induced endothelial impairment in obese Lewis dwarf rats: implications for vascular aging. J. Gerontol. A Biol. Sci. Med. Sci. 2012, 67:553-564.
7. Rodionov R.N., Dayoub H., Lynch C.M., Wilson K.M., Stevens J.W., Murry D.J., Kimoto M., Arning E., Bottiglieri T., Cooke J.P., Baumbach G.L., Faraci F.M., Lentz S.R. Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia. Circ. Res. 2010, 106:551-558.
8. Miyazaki H., Matsuoka H., Cooke J.P., Usui M., Ueda S., Okuda S., Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. J. Cardiol. 1999, 33:105-106.
9. Capaldo B., Guardasole V., Pardo F., Matarazzo M., Di Rella F., Numis F., Merola B., Longobardi S., Saccà L. Abnormal vascular reactivity in growth hormone deficiency. Circulation 2001, 103:520-524.
10. Setola E., Monti L.D., Lanzi R., Lucotti P., Losa M., Gatti E., Galluccio E., Oldani M., Fermo I., Giovannelli M., Bosi E., Piatti P. Effects of growth hormone treatment on arginine to asymmetric dimethylarginine ratio and endothelial function in patients with growth hormone deficiency. Metabolism 2008, 57:1685-1690.
11. Veresh Z., Debreczeni B., Hamar J., Kaminski P.M., Wolin M.S., Koller A. Asymmetric dimethylarginine reduces nitric oxide donor-mediated dilation of arterioles by activating the vascular renin-angiotensin system and reactive oxygen species. J. Vasc. Res. 2012, 49:363-372.
12. Ayer J.G., Harmer J.A., Nakhla S., Xuan W., Ng M.K., Raitakari O.T., Marks G.B., Celermajer D.S. HDL-cholesterol, blood pressure, and asymmetric dimethylarginine are significantly associated with arterial wall thickness in children. Arterioscler. Thromb. Vasc. Biol. 2009, 29:943-949.
13. Metwalley K.A., Farghaly H.S., Abd El-Hafeez H.A. Evaluation of left ventricular mass and function, lipid profile, and insulin resistance in Egyptian children with growth hormone deficiency: a single-center prospective case-control study. Indian J. Endocrinol. Metab. 2013, 17:876-882.
14. Salerno M., Esposito V., Farina V., Radetti G., Umbaldo A., Capalbo D., Spinelli L., Muzzica S., Lombardi G., Colao A. Improvement of cardiac performance and cardiovascular risk factors in children with GH deficiency after two years of GH replacement therapy: an observational, open, prospective, case-control study. J. Clin. Endocrinol. Metab. 2006, 91:1288-1295.
15. Capalbo D., Mattace Raso G., Esposito A., Di Mase R., Barbieri F., Meli R., Bruzzese D., Salerno M. Cluster of cardiometabolic risk factors in children with GH deficiency: a prospective, case-control study. Clin. Endocrinol. (Oxf) 2014, 80:856-862.
16. GH Research Society Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J. Clin. Endocrinol. Metab. 2000, 85:3990-3993.
17. Cacciari E., Milani S., Balsamo A., Spada E., Bona G., Cavallo L., Cerutti F., Gargantini L., Greggio N., Tonini G., Cicognani A. Italian cross-sectional growth charts for height, weight and BMI (2 to 20yr). J. Endocrinol. Invest. 2006, 29:581-593.
18. Tremblay A.J., Morrissette H., Gagné J.M., Bergeron J., Gagnè C., Couture P. Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with beta-quantification in a large population. Clin. Biochem. 2004, 37:785-790.
19. Matthew D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
20. Colao A., Di Somma C., Spiezia S., Savastano S., Rota F., Savanelli M.C., Lombardi G. Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J. Clin. Endocrinol. Metab. 2008, 93:3416-3424.
21. Colao A., Di Somma C., Spiezia S., Rota F., Pivonello R., Savastano S., Lombardi G. The natural history of partial growth hormone deficiency in adults: a prospective study on the cardiovascular risk and atherosclerosis. J. Clin. Endocrinol. Metab. 2006, 91:2191-2200.
22. Palmeiro C.R., Anand R., Dardi I.K., Balasubramaniyam N., Schwarcz M.D., Weiss I.A. Growth hormone and the cardiovascular system. Cardiol. Rev. 2012, 20:197-207.
23. Abs R., Feldt-Rasmussen U., Mattsson A.F., Monson J.P., Bengtsson B.A., Góth M.I., Wilton P., Koltowska-Häggström M. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults: a KIMS database analysis. Eur. J. Endocrinol. 2006, 155:79-90.
24. Böger R.H. Asymmetric dimethylarginine (ADMA) modulates endothelial function-therapeutic implications. Vasc. Med. 2003, 8:149-151.
25. Deepak D., Daousi C., Javadpour M., Clark D., Perry Y., Pinkney J., MacFarlane I.A. The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency. Growth Hormon. IGF Res. 2010, 20:220-225.
26. Cooke J.P. Asymmetrical dimethylarginine: the Über marker?. Circulation 2004, 109:1813-1819.
27. Valkonen V.P., Päivä H., Salonen J.T., Lakka T.A., Lehtimäki T., Laakso J., Laaksonen R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001, 358:2127-2128.
28. Zoccali C., Bode-Böger S., Mallamaci F., Benedetto F., Tripepi G., Malatino L., Cataliotti A., Bellanuova I., Fermo I., Frölich J., Böger R. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001, 358:2113-2117.
29. Yoo J.H., Lee S.C. Elevated levels of plasma homocysteine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001, 158:425-430.
30. Thum T., Fleissner F., Klink I., Tsikas D., Jakob M., Bauersachs J., Stichtenoth D.O. Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-1. J. Clin. Endocrinol. Metab. 2007, 92:4172-4179.
31. Tivesten A., Barlind A., Caidahl K., Klintland N., Cittadini A., Ohlsson C., Isgaard J. Growth hormone-induced blood pressure decrease is associated with increased mRNA levels of the vascular smooth muscle KATP channel. J. Endocrinol. 2004, 183:195-202.
32. Rochette L., Lorin J., Zeller M., Guilland J.C., Lorgis L., Cottin Y., Vergely C. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?. Pharmacol. Ther. 2013, 140:239-257.
33. Smith J.C., Evans L.M., Wilkinson I., Goodfellow J., Cockcroft J.R., Scanlon M.F., Davies J.S. Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. Clin. Endocrinol. (Oxf) 2002, 56:493-501.
34. Russell-Jones D.L., Watts G.F., Weissberger A., Naoumova R., Myers J., Thompson G.R., Sönksen P.H. The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clin. Endocrinol. (Oxf) 1994, 41:345-350.
35. Tran C.T., Leiper J.M., Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler. Suppl. 2003, 4:33-40.
36. Mohn A., Marzio D., Giannini C., Capanna R., Marcovecchio M., Chiarelli F. Alterations in the oxidant-antioxidant status in prepubertal. Clin. Endocrinol. (Oxf) 2005, 63:537-542.
37. Jørgensen A.P., Fougner K.J., Ueland T., Gudmundsen O., Burman P., Schreiner T. Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency. Growth Hormon. IGF Res. 2011, 21:69-75.
38. Newman C.B., Frisch K.A., Rosenzweig B., Roubenoff R., Rey M., Kidder T., Kong Y., Pursnani A., Sedlis S.P., Schwartzbard A., Kleinberg D.L. Moderate doses of hGH (0.64mg/d) improve lipids but not cardiovascular function in GH-deficient adults with normal baseline cardiac function. J. Clin. Endocrinol. Metab. 2011, 96:122-132.
39. Lanes R., Soros A., Gunczler P., Paoli M., Carrillo E., Villaroel O., Palacios A. Growth hormone deficiency, low levels of adiponectin, and unfavorable plasma lipid and lipoproteins. J. Pediatr. 2006, 149:324-329.
40. Monson J.P., Jonsson P., Koltowska-Haggstrom M., Kourides I. Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy. Clin. Endocrinol. (Oxf) 2007, 67:623-628.